<DOC>
	<DOCNO>NCT02435342</DOCNO>
	<brief_summary>The primary purpose study examine safety outcome active plaque psoriasis patient systemic administration dalazatide . Clinical outcome measure also assess .</brief_summary>
	<brief_title>A 4 Week Study Safety , Tolerability , Pharmacodynamics ShK-186 ( Dalazatide ) Active Plaque Psoriasis</brief_title>
	<detailed_description>The primary purpose study examine safety outcome active plaque psoriasis patient systemic administration dalazatide . Clinical outcome measure also assess .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Adult male female subject , age 1865 ; 2 . Active plaque psoriasis â‰¥3 % BSA involve ; 3 . An adequate number vulgar psoriatic plaque least 2 cm X 2 cm Target Lesion Investigator Global Assessment score &gt; 3 , locate face , scalp , groin , genitals , fold , palm sole 4 . Weight 50 100 kg ; 5 . Nonchild bear potential willingness use adequate contraception order prevent pregnancy screen visit 60 day followup visit . 6 . Subject evaluated latent TB infection . 7 . Able communicate able provide valid , write informed consent ; The following exclude potential subject study : 1 . Erythrodermic , predominantly guttate , exclusively palmar/plantar , generalize pustular psoriasis ; 2 . Current druginduced aggravated psoriasis ( e.g. , new onset psoriasis exacerbation psoriasis betablockers , calciumchannel blocker , lithium carbonate ) ; 3 . Use follow concurrent systemic medication : corticosteroid , retinoids , cyclosporine , methotrexate , biologic agent . 4 . Use concurrent topical medication ( must discontinue least 2 week prior baseline ) ; 5 . UVA UVB therapy within 4 week baseline ; 6 . The presence uncontrolled hypertension , uncontrolled diabetes , clinically significant cardiovascular disease , asthma reduce pulmonary capacity , history seizure neurologic disorder ; 7 . Presence history preexist paresthesia neuropathy ; 8 . Abnormalities neurological exam screen baseline ; 9 . Clinically significant ECG abnormality , opinion Investigator ; 10 . History cancer require systemic chemotherapy radiation ; 11 . The presence acute infection history acute infection judge Investigator within 7 day baseline ; 12 . The presence clinically significant laboratory abnormality ; 13 . A positive hepatitis screen ( Hepatitis BsAg antiHCV ) positive Human Immunodeficiency Virus ( HIV ) antibody test ; 14 . History treat untreated TB 15 . Any history anaphylaxis important view Investigator ; 16 . Participation another clinical trial receipt investigational product within 90 day baseline ( 5 halflives previous drug , whichever long ) ; 17 . History alcohol abuse important view Investigator ; 18 . Positive drug screen amphetamine , barbituates , benzodiazepine , cocaine , cannabis , methamphetamine , methylenedioxymethanphetamine , opiates phencyclidine 19 . Inadequate venous access would interfere obtain blood sample ; 20 . Positive pregnancy test screen baseline current lactation ( female subject ) ; 21 . Inability unwillingness comply study restriction , return follow appointment , consideration , opinion Investigator , would make candidate unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>ShK-186</keyword>
	<keyword>dalazatide</keyword>
	<keyword>psoriasis</keyword>
	<keyword>Kv1.3 ,</keyword>
	<keyword>autoimmune</keyword>
</DOC>